Moxifloxacin (BAY 12–8039) is a new 8‐methoxy‐fluoroquinolone antibacterial agent. The
minimum inhibitory concentration for 90% of organisms (MIC90) is less than 0.25 mg/L for …

Assessment of pharmacodynamic activity from standard in vitro minimum inhibitory
concentrations (MICs) alone is insufficient to predict in vivo potency. Achievable serum and …

Chronic bronchitis is common among adults and infectious exacerbations contribute
considerably to morbidity and mortality. We aimed to compare the safety and efficacy of …

Gatifloxacin, grepafloxacin, moxifloxacin and trovafloxacin are fluoroquinolones with
enhanced Gram-positive activity while retaining broad-spectrum activity against Gram …

The aim of this multicentre, randomized study was to compare the efficacy and safety of
moxifloxacin (BAY 12-8039), a new 8-methoxy fluoroquinolone, with that of cefuroxime axetil …

The aim of this study was to develop a high-performance liquid chromatographic (HPLC)
assay for the determination of moxifloxacin in human plasma and lung tissue. The assay …

Moxifloxacin is a recently developed fluoroquinolone antibiotic. It is rapidly absorbed
following oral administration, reaching a mean peak drug plasma concentration (C (max)) of …

As the most commonly used fluoroquinolone in the United States since 1987, ciprofloxacin
has exerted the greatest selective pressure on S. pneumoniae and provides a valuable …

To benchmark the activity of moxifloxacin (a newer fluoroquinolone), a US study comprising
16,141 contemporary isolates of Streptococcus pneumoniae (5,640), Haemophilus …

Community-acquired pneumonia (CAP) remains a common and serious illness with
approximately 2–4 million cases reported annually. Management of CAP is therapeutically …